Search
Tirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigational[L27806] Actinic keratosis is a chronic condition characterized by lesions, which can potentially transform into invasive squamous cell carcinoma with a risk of 1% over 10 years. … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigational[L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing. … Orforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTrilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersLactobacillus acidophilus
go.drugbank.com/drugs/DB15823ApprovedInvestigationalMixtures: GYNOFLOR 50 MG/0.03 MG VAJİNAL TABLET, 6 ADET, GYNOFLOR 50 MG/0.03 MG VAJİNAL TABLET, 12 ADETTecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigationalHowever, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. … The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980.
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A InducersMedrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawnMedrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone.
Mixtures: PRESOMEN 28 COMP 0.3/5MG, PRESOMEN 28 COMP 0.3/5MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMF-300
go.drugbank.com/drugs/DB32060InvestigationalMF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase. … As a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983]
Enristomig
go.drugbank.com/drugs/DB29060InvestigationalINBRX-105 is a biologic drug. … INBRX-105 is under investigation in clinical trial NCT03809624 (Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer).
Bacillus calmette-guerin substrain russian BCG-I live antigen
go.drugbank.com/drugs/DB16648ApprovedInvestigationalthought to work by stimulating a local immune and inflammatory response in the bladder. … [L32729,A232264] The live Russian BCG-I substrain of BCG was granted a notice of compliance with conditions by Health Canada in February 2021.
Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19344ApprovedInvestigationalpneumoniae_ serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197). … Streptococcus pneumoniae type deOAc15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains de-O-acetylated saccharides of the capsular antigens of _Streptococcus